AbbVie files risankizumab in the US
AbbVie has filed risankizumab in the US seeking approval for its use to treat moderate-to-severe plaque psoriasis.
Read More
Tag: PASI
Psoriasis patients get NHS access to LEO Pharma’s Kyntheum
Cost regulators for NHS therapies in England and Wales have now published final guidelines backing the use of LEO Pharma’s Kyntheum as an option for treating severe plaque psoriasis.
Read More
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
